KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Liabilities and Shareholders Equity: 2011-2024

Historic Liabilities and Shareholders Equity for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Dec 2024 value amounting to $1.4 billion.

  • Supernus Pharmaceuticals' Liabilities and Shareholders Equity rose 5.74% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 billion, marking a year-over-year increase of 5.29%. This contributed to the annual value of $1.4 billion for FY2024, which is 7.08% up from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Liabilities and Shareholders Equity of $1.4 billion as of FY2024, which was up 7.08% from $1.3 billion recorded in FY2023.
  • Supernus Pharmaceuticals' 5-year Liabilities and Shareholders Equity high stood at $1.7 billion for FY2022, and its period low was $1.3 billion during FY2023.
  • In the last 3 years, Supernus Pharmaceuticals' Liabilities and Shareholders Equity had a median value of $1.4 billion in 2024 and averaged $1.4 billion.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Liabilities and Shareholders Equity increased by 29.63% in 2020, and later fell by 24.95% in 2023.
  • Over the past 5 years, Supernus Pharmaceuticals' Liabilities and Shareholders Equity (Yearly) stood at $1.5 billion in 2020, then climbed by 12.30% to $1.7 billion in 2021, then grew by 0.79% to $1.7 billion in 2022, then declined by 24.95% to $1.3 billion in 2023, then climbed by 7.08% to $1.4 billion in 2024.